AngioDynamics (ANGO) Tops Q1 EPS by 9c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AngioDynamics Reports Fiscal 2021 First Quarter Financial Results
September 29, 2020 7:00 AM EDTFiscal 2021 First Quarter Highlights
Net sales of $70.2 million increased 6.3% compared to the prior-year quarter, inclusive of the previously disclosed $5.2 million order from the National Health Service (NHS) in the UK Gross margin declined 700 basis points year over year to 50.9% GAAP loss per share of $0.11 and adjusted earnings per share of $0.02 Cash and cash equivalents on August 31, 2020 were $47.9 million, compared to $54.4 million on May 31, 2020 The Company expects fiscal year 2021 net sales between $278 and $284 million and fiscal year 2021 adjusted earnings per share between $0.00 and $0.05... More